Tentt

BioProtect Acquired by Olympus | Healthcare M&A Deal

Announced
HealthcarePlatform

Deal Overview

Olympus has acquired BioProtect, a medical devices business in the urology space, for $270 million. Olympus acquisitions expand its urological technologies portfolio aimed at improving prostate cancer accessibility, with BioProtect focused on prostate-related medical device solutions. BioProtect acquisition supports Olympus acquisitions in healthcare M&A by strengthening product capabilities for urology clinicians and patients. The platform acquisition is a strategic acquisition by Olympus, with deal value also referenced at $14.5 million, and is categorized as an announced healthcare M&A transaction.

Key Details

Transaction
Olympus acquires BioProtect
Deal Size
Over $100M
Reported Value
$270 million

Filed under

Source

Read full article on prnewswire.com

via GN - signed definitive agreement · May 26, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →